Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL16467215 | 0.88 | MAOB (0.41) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL30578887 | 0.83 | ALDH1A1 (0.52) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| Propionic Acid SCHEMBL11195372 | 0.82 | MTNR1A (0.41) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL19638404 | 0.81 | ALDH1A1 (0.50) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| Benzofuran SCHEMBL28223437 | 0.76 | ALDH1A1 (0.63) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL13947728 | 0.73 | MAOA (0.46) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL827237 | 0.71 | MAOA (0.50) | TSHRMAOAMAOBFTOKCNA3 | |
| SCHEMBL275378 | 0.71 | MAOA (0.45) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL788355 | 0.71 | MAOA (0.45) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL275377 | 0.71 | MAOA (0.50) | CYP3A4TSHRALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20240400531-A1 | HERBICIDAL MALONAMIDES CONTAINING A CONDENSED RING SYSTEM | BASF SE (DE) | 2024-12-05 | — | — | US | disclosed |
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4442685-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-118515595-A | Deep blue fluorescent molecule based on 2,2' -bisindole skeleton and preparation method and application thereof | 泰州学院 | 2024-08-20 | — | — | CN | disclosed |
| EP-4396173-A1 | HERBICIDAL MALONAMIDES CONTAINING A CONDENSED RING SYSTEM | BASF SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-6140331-A | FOR TREATING ANXIETY DISORDERS, DEPRESSION, PSYCHOSIS, IMPULSE CONTROL DISORDERS, ALCOHOL ABUSE, ISCHAEMIC DISEASES, CARDIOVASCULAR DISORDERS, SIDE EFFECTS INDUCED BY CONVENTIONAL ANTIPSYCHOTIC AGENTS AND SENILE DEMENTIA | H. LUNDBECK A/S (DK) | 2000-10-31 | — | — | US | disclosed |
| EP-0673375-B1 | FUSED BENZO COMPOUNDS | LUNDBECK & CO AS H (DK) | 1999-02-24 | — | — | EP | disclosed |
| US-5753661-A | TREATMENT OF NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| EP-0812321-A1 | PROKINETIC OXADIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-12-17 | — | — | EP | disclosed |
| WO-1996026937-A1 | PROKINETIC OXADIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-06 | — | — | WO | disclosed |
| EP-0673375-A1 | FUSED BENZO COMPOUNDS | H. LUNDBECK A/S (DK) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013659-A1 | FUSED BENZO COMPOUNDS | H. LUNDBECK A/S (DK) | 1994-06-23 | — | — | WO | disclosed |
| EP-0079683-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-06 | — | — | EP | disclosed |
| US-4514211-A | HERBICIDES, PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0079683-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | CYP3A4 2478/4885TSHR 2513/4885ALDH1A1 3042/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | CYP3A4 4531/4885TSHR 144/4885ALDH1A1 2560/4885 |
| US-20240400531-A1 | HERBICIDAL MALONAMIDES CONTAINING A CONDENSED RING SYSTEM | DDT, ME3, ME1 | CYP3A4 165/4885TSHR 3945/4885ALDH1A1 1099/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | CYP3A4 4495/4885TSHR 4379/4885ALDH1A1 4614/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | CYP3A4 4823/4885TSHR 4588/4885ALDH1A1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.